Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Sarcoma × dabrafenib × Clear all

Phase

Status

Active not recruiting 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Melanoma 68 Neoplasms 25 Neoplasm Metastasis 11 Carcinoma, Non-Small-Cell Lung 10 Thyroid Carcinoma, Anaplastic 9 Thyroid Neoplasms 8 Glioma 8 Brain Neoplasms 8 Skin Neoplasms 6 Multiple Myeloma 6 Hematologic Neoplasms 5 Colorectal Neoplasms 4 Ameloblastoma 4 Thyroid Cancer, Papillary 3 Glioblastoma 3 Astrocytoma 3 Parkinson Disease 4, Autosomal Dominant Lewy Body 2 Oligodendroglioma 2 Neurocytoma 2 Lymphoma, Non-Hodgkin 2 Lung Neoplasms 2 Histiocytosis, Langerhans-Cell 2 Ganglioneuroma 2 Ganglioglioma 2 Fever 2 Unspecified Adult Solid Tumor, Protocol Specific 1 Thyroid cancer, follicular 1 Thyroid cancer, Hurthle cell 1 Thrombocytosis 1 Solid Tumor 1

Interventions

Doxorubicin 127 Ifosfamide 76 Radiotherapy 73 Cyclophosphamide 64 Gemcitabine 54 Filgrastim 48 pazopanib 38 pembrolizumab 36 Trabectedin 36 Etoposide 36 Docetaxel 35 Vincristine 34 Cisplatin 30 Nivolumab 29 Magnetic Resonance Spectroscopy 23 Irinotecan 23 Carboplatin 22 Temozolomide 20 Surgical Procedures, Operative 20 Radiation 20 Ipilimumab 20 Mesna 17 Granulocyte Colony-Stimulating Factor 17 Biopsy 17 Bevacizumab 17 Sirolimus 16 Melphalan 16 Blood Specimen Collection 16 eribulin 15 anlotinib 15

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT03784014 2025-12-11

MULTISARC

Institut National de la Santé Et de la Recherche Médicale, France

Phase 3 Active not recruiting

Neoplasm Metastasis, Sarcoma

Data powered by HemOnc (CC BY 4.0) Colophon ⚡